Allogene Therapeutics (ALLO) Goldman Sachs Cell Therapy Day summary

Industry outlook and scientific advancements

• Allogeneic cell therapy is positioned as the next frontier, aiming for scalable, off-the-shelf treatments for hematologic malignancies, solid tumors, and autoimmune diseases.

• Overcoming immune rejection is central, with strategies like 'cloak' (immune evasion) and 'dagger' (targeting alloreactive T cells) being developed.

• Manufacturing science and facility investments are enabling production at scales far exceeding autologous approaches.

• Early clinical data show allogeneic CAR T therapies can match autologous efficacy and durability in certain settings.

• The field is moving toward reducing or eliminating lymphodepletion, especially for autoimmune indications.

Pipeline updates and clinical development

• Lead allogeneic CAR T program cema-cel is in a pivotal frontline study for large B-cell lymphoma, with key milestones through 2027.

• ALLO-316, a CD70-targeted CAR T, is being studied in renal cell carcinoma, with updated data expected by year-end.

• ALLO-329, a dual CD19/CD70 CAR, is advancing for autoimmune diseases, aiming for IND submission in Q1 2025 and clinical proof-of-concept by year-end 2025.

• Sana is pursuing stem cell-derived therapies for type 1 diabetes, focusing on eliminating the need for immunosuppression and scaling manufacturing.

• Early phase I data for CD19 CARs in autoimmune and B-cell malignancies show promising safety and B-cell depletion.

Commercialization, scalability, and manufacturing

• Allogeneic manufacturing facilities can produce tens of thousands of doses annually, supporting large-scale indications.

• Supply chain complexity and early capital investment are challenges, but scalability and cost advantages are significant if biology is validated.

• Off-the-shelf allogeneic products simplify logistics, reduce barriers for site activation, and can address much larger patient populations.

• Manufacturing advances and gene engineering are expected to further reduce costs and improve product profiles.

• Donor variability and product release quality are key focus areas for ensuring consistent safety and efficacy.